The University of North Carolina and the University of Wisconsin have collaborated on developing a new anti-cancer drug candidate, called CB-2PA-NT, that may have a wide application.

This research lays the groundwork for future studies to use CB-2PA-NT in human imaging, although, regulatory approval is still needed before these studies can commence.

New study findings, presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2023), position CB-2PA-NT as a promising candidate for an innovative theranostics strategy.

Theranostics presents a powerful strategy in the fight against cancer, combining two essential elements. It involves identifying cancer cells throughout the body and administering specialized radiation to eliminate them.

Read the full article here.